- Home
- KNOP vs OCGN Comparison
KNOP vs OCGN Comparison
Compare KNOP & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | OCGN |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 419.8M |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KNOP | OCGN |
|---|---|---|
| Price | $10.26 | $1.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 86.2K | ★ 5.1M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 31.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.51 | N/A |
| Revenue Next Year | N/A | $1,718.38 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.16 | $0.90 |
| 52 Week High | $11.78 | $2.73 |
Technical Indicators
Market Signals| Indicator | KNOP | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 39.17 |
| Support Level | $10.04 | $1.09 |
| Resistance Level | $10.88 | $1.92 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 1.83 | 27.45 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").